European medical academic societies have been cooperating on research projects and organising Continuing Medical Education. In 2009, for the first time, a meeting of these societies was convened. The focus of the meeting was on cooperation with the European Commission with a view on strengthening the funding for medical research. It was also intended to facilitate discussions on other policies related to European health research and on enhancing the visibility of EU health research.

In 2010, the European Association of the Study of Diabetes (EASD), the European Society of Cardiology (ESC), the European Cancer Organisation and the European Respiratory Society (ERS) jointly founded the Alliance for Biomedical Research in Europe. The BioMed Alliance expanded over the subsequent years and its members started cooperating on an increasing number of topics related to health policy. During the general assembly in 2018, members decided to change the name to ‘Biomedical Alliance in Europe’ to reflect the wider focus beyond just health research policy. Members are now cooperating and adopting common positions on a range of subjects from health research to continuing medical education, the regulatory framework for medical devices and the regulation of clinical trials


The BioMed Alliance is a not-for-profit organisation. In pursuit of its goals and objectives, the Biomedical Alliance in Europe may generate the required financial revenue from membership dues, charitable support or any other source that the Board of Directors may, in its sole discretion, deem constructive and appropriate. However, in order to guarantee its impartiality and independence, the BioMed Alliance will not accept donations or any other income from the health-related industry. Most of our funding comes from membership fees, and a small proportion of our annual income includes compensation for our participation in the EU Projects CORE-MD, BEWELL and EXHALE. The BioMed Alliance is also registered in the EU Transparency Register, for more information see our entry here.